Home > Research > Publications & Outputs > Bipolar disorder in youth is associated with in...

Links

Text available via DOI:

View graph of relations

Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. / Petrov, Brawnie; Aldoori, Ayat; James, Cindy et al.
In: Translational Psychiatry, Vol. 8, 61, 13.03.2018.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Petrov, B, Aldoori, A, James, C, Yang, K, Perez Algorta, GD, Lee, A, Zhang, L, Lin, T, Al Awadhi, R, Parquette, J, Samogyi, A, Arnold, LE, Fristad, MA, Gracious , B & Ziouzenkova, O 2018, 'Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein', Translational Psychiatry, vol. 8, 61. https://doi.org/10.1038/s41398-018-0109-7

APA

Petrov, B., Aldoori, A., James, C., Yang, K., Perez Algorta, G. D., Lee, A., Zhang, L., Lin, T., Al Awadhi, R., Parquette, J., Samogyi, A., Arnold, L. E., Fristad, M. A., Gracious , B., & Ziouzenkova, O. (2018). Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Translational Psychiatry, 8, Article 61. https://doi.org/10.1038/s41398-018-0109-7

Vancouver

Petrov B, Aldoori A, James C, Yang K, Perez Algorta GD, Lee A et al. Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. Translational Psychiatry. 2018 Mar 13;8:61. doi: 10.1038/s41398-018-0109-7

Author

Petrov, Brawnie ; Aldoori, Ayat ; James, Cindy et al. / Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein. In: Translational Psychiatry. 2018 ; Vol. 8.

Bibtex

@article{161ad144d5e547d7919211118ab2961b,
title = "Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein",
abstract = "Genetic, dietary, and inflammatory factors contribute to the etiology of major mood disorders (MMD), thus impeding the identification of specific biomarkers to assist in diagnosis and treatment. We tested association of vitamin D and inflammatory markers in 36 adolescents with bipolar disorder (BD) and major depressive disorder (MDD) forms of MMD and without MMD (non-mood control). We also assessed the overall level of inflammation using a cell-based reporter assay for nuclear factor kappa-B (NFκB) activation and measuring antibodies to oxidized LDL. We found that these factors were similar between non-mood and MMD youth. To identify potential biomarkers, we developed a screening immunoprecipitation-sequencing approach based on inflammatory brain glia maturation factor beta (GMFβ). We discovered that a homolog of GMFβ in human plasma is vitamin D-binding protein (DBP) and validated this finding using immunoprecipitation with anti-DBP antibodies and mass spectrometry/sequencing analysis. We quantified DBP levels in participants by western blot. DBP levels in BD participants were significantly higher (136%) than in participants without MMD (100%). The increase in DBP levels in MDD participants (121.1%) was not statistically different from these groups. The DBP responds early to cellular damage by binding of structural proteins and activating inflammatory cells. A product of enzymatic cleavage of DBP has been described as macrophage-activating factor. Circulating DBP is comprised of heterogenous high and low molecular fractions that are only partially recognized by mono- and polyclonal ELISA and are not suitable for the quantitative comparison of DBP in non-mood and MDD participants. Our data suggest DBP as a marker candidate of BD warranting its validation in a larger cohort of adolescent and adult MMD patients.",
keywords = "Biomarkers, Diagnostic markers",
author = "Brawnie Petrov and Ayat Aldoori and Cindy James and Kefeng Yang and {Perez Algorta}, {Guillermo Daniel} and Aejin Lee and Liwen Zhang and Tao Lin and {Al Awadhi}, Reem and Johnathan Parquette and Arpad Samogyi and Arnold, {L. Eugene} and Fristad, {Mary. A} and Barbara Gracious and Ouliana Ziouzenkova",
year = "2018",
month = mar,
day = "13",
doi = "10.1038/s41398-018-0109-7",
language = "English",
volume = "8",
journal = "Translational Psychiatry",
issn = "2158-3188",
publisher = "Nature Publishing Group",

}

RIS

TY - JOUR

T1 - Bipolar disorder in youth is associated with increased levels of vitamin D-binding protein

AU - Petrov, Brawnie

AU - Aldoori, Ayat

AU - James, Cindy

AU - Yang, Kefeng

AU - Perez Algorta, Guillermo Daniel

AU - Lee, Aejin

AU - Zhang, Liwen

AU - Lin, Tao

AU - Al Awadhi, Reem

AU - Parquette, Johnathan

AU - Samogyi, Arpad

AU - Arnold, L. Eugene

AU - Fristad, Mary. A

AU - Gracious , Barbara

AU - Ziouzenkova, Ouliana

PY - 2018/3/13

Y1 - 2018/3/13

N2 - Genetic, dietary, and inflammatory factors contribute to the etiology of major mood disorders (MMD), thus impeding the identification of specific biomarkers to assist in diagnosis and treatment. We tested association of vitamin D and inflammatory markers in 36 adolescents with bipolar disorder (BD) and major depressive disorder (MDD) forms of MMD and without MMD (non-mood control). We also assessed the overall level of inflammation using a cell-based reporter assay for nuclear factor kappa-B (NFκB) activation and measuring antibodies to oxidized LDL. We found that these factors were similar between non-mood and MMD youth. To identify potential biomarkers, we developed a screening immunoprecipitation-sequencing approach based on inflammatory brain glia maturation factor beta (GMFβ). We discovered that a homolog of GMFβ in human plasma is vitamin D-binding protein (DBP) and validated this finding using immunoprecipitation with anti-DBP antibodies and mass spectrometry/sequencing analysis. We quantified DBP levels in participants by western blot. DBP levels in BD participants were significantly higher (136%) than in participants without MMD (100%). The increase in DBP levels in MDD participants (121.1%) was not statistically different from these groups. The DBP responds early to cellular damage by binding of structural proteins and activating inflammatory cells. A product of enzymatic cleavage of DBP has been described as macrophage-activating factor. Circulating DBP is comprised of heterogenous high and low molecular fractions that are only partially recognized by mono- and polyclonal ELISA and are not suitable for the quantitative comparison of DBP in non-mood and MDD participants. Our data suggest DBP as a marker candidate of BD warranting its validation in a larger cohort of adolescent and adult MMD patients.

AB - Genetic, dietary, and inflammatory factors contribute to the etiology of major mood disorders (MMD), thus impeding the identification of specific biomarkers to assist in diagnosis and treatment. We tested association of vitamin D and inflammatory markers in 36 adolescents with bipolar disorder (BD) and major depressive disorder (MDD) forms of MMD and without MMD (non-mood control). We also assessed the overall level of inflammation using a cell-based reporter assay for nuclear factor kappa-B (NFκB) activation and measuring antibodies to oxidized LDL. We found that these factors were similar between non-mood and MMD youth. To identify potential biomarkers, we developed a screening immunoprecipitation-sequencing approach based on inflammatory brain glia maturation factor beta (GMFβ). We discovered that a homolog of GMFβ in human plasma is vitamin D-binding protein (DBP) and validated this finding using immunoprecipitation with anti-DBP antibodies and mass spectrometry/sequencing analysis. We quantified DBP levels in participants by western blot. DBP levels in BD participants were significantly higher (136%) than in participants without MMD (100%). The increase in DBP levels in MDD participants (121.1%) was not statistically different from these groups. The DBP responds early to cellular damage by binding of structural proteins and activating inflammatory cells. A product of enzymatic cleavage of DBP has been described as macrophage-activating factor. Circulating DBP is comprised of heterogenous high and low molecular fractions that are only partially recognized by mono- and polyclonal ELISA and are not suitable for the quantitative comparison of DBP in non-mood and MDD participants. Our data suggest DBP as a marker candidate of BD warranting its validation in a larger cohort of adolescent and adult MMD patients.

KW - Biomarkers

KW - Diagnostic markers

U2 - 10.1038/s41398-018-0109-7

DO - 10.1038/s41398-018-0109-7

M3 - Journal article

VL - 8

JO - Translational Psychiatry

JF - Translational Psychiatry

SN - 2158-3188

M1 - 61

ER -